

International Journal of Pharmacology and Clinical Research



ISSN Print: 2664-7613
ISSN Online: 2664-7621
Impact Factor: (RJIF) 8.29
IJPCR 2025; 7(2): 379-385
www.pharmacologyjournal.in
Received: 06-08-2025
Accepted: 09-09-2025

Mallavarapu Veda
Pursuing Bachelor of
Pharmacy at Rathnam
Institute of Pharmacy,
Pidathapolur, Nellore,
Andhra Pradesh, India

Dr. Y Prapurna Chandra
Ph.D., Principal of Rathnam
Institute of Pharmacy,
Pidathapolur, Nellore. Ph.D.
in Pharmacology, KLE
University, Belgaum,
Karnataka, India

K Kavyasudha
1) M.Pharm P.Cology, Faculty-
Associate Professor of
Pharmacology, Rathnam
Institute of Pharmacy,
Pidathapolur, Nellore,
Andhra Pradesh, India
2) M.Pharm. in Pharmacology,
Sree Venkateshwara
University, Tirupati,
Andhra Pradesh, India

Corresponding Author:
Mallavarapu Veda
Pursuing Bachelor of
Pharmacy at Rathnam
Institute of Pharmacy,
Pidathapolur, Nellore,
Andhra Pradesh, India

Integration of natural products with modern therapies for gastrointestinal disorders

Mallavarapu Veda, Y Prapurna Chandra and K Kavyasudha

DOI: <https://www.doi.org/10.33545/26647613.2025.v7.i2e.134>

Abstract

Gastrointestinal (GI) disorders, Including Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and functional dyspepsia, pose major global health challenges due to their chronic nature and significant impact on quality of life. Conventional pharmacological therapies such as proton pump inhibitors, corticosteroids, and biologics are effective but often limited by side effects, drug resistance, and incomplete symptom control. Increasing evidence supports the integration of natural products, particularly plant-derived compounds like curcumin, berberine, and flavonoids, into GI disorder management. These natural compounds exhibit potent anti-inflammatory, antioxidant, antimicrobial, and gut microbiota-modulating effects, offering complementary benefits alongside conventional treatments. Mechanistically, they regulate immune responses, enhance mucosal healing, improve gut motility, and restore microbial balance. Integrative approaches combining natural and modern therapies demonstrate synergistic effects, reducing drug dosage and improving therapeutic outcomes. However, safety, standardization, and regulatory challenges remain critical for clinical application. Future research focusing on personalized medicine, pharmacokinetics, and advanced formulations may enhance the efficacy and safety of these compounds.

Keywords: Gastrointestinal disorders, natural products, curcumin, berberine, flavonoids, gut microbiota, integrative therapy

1. Introduction

Gastrointestinal (GI) disorders, encompassing conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and functional dyspepsia, present significant challenges to public health globally [1]. These disorders often lead to chronic symptoms and diminished quality of life, necessitating effective and sustainable treatment strategies [2]. While conventional pharmacological therapies have been employed to manage these conditions, their limitations, including side effects and incomplete symptom control, have prompted interest in integrating natural products into treatment regimens [3].




Fig 1: A comparative view of natural products and modern therapies

Natural products, particularly those derived from herbal medicine, have been utilized for centuries in various cultures to treat digestive ailments ^[4].

Zhu X, Wang K, Zhang K, Xu F, Ye C, Xu B. Integration of natural products and modern medicine in gut-brain axis modulation: A potential strategy for gastrointestinal disorders. *Frontiers in Pharmacology*. 2022;13:879456.

Modern scientific research has begun to elucidate the mechanisms through which these natural compounds exert therapeutic effects on the GI system ^[5]. For instance, bioactive compounds such as curcumin, berberine, and flavonoids have demonstrated anti-inflammatory, antioxidant, and gut microbiota-modulating properties, which are beneficial in managing GI disorders ^[6]. The integration of natural products with conventional therapies offers a holistic approach to GI disorder management ^[7]. This integrative strategy aims to enhance therapeutic outcomes by combining the strengths of both modalities ^[8]. Natural products can complement conventional treatments by addressing underlying pathophysiological mechanisms, such as inflammation and gut dysbiosis, thereby improving symptom control and reducing the reliance on pharmacological agents ^[9]. However, the integration of natural products into modern therapeutic frameworks is not without challenges ^[10]. Issues related to standardization, quality control, and potential herb-drug interactions necessitate rigorous clinical evaluation and regulatory oversight ^[11]. Therefore, collaborative efforts between traditional medicine practitioners, researchers, and clinicians are essential to develop evidence-based guidelines for the safe and effective use of natural products in GI disorder management ^[12]. In conclusion, the integration of natural products with modern therapies holds promise for advancing the management of gastrointestinal disorders ^[13]. Through a multidisciplinary approach that combines traditional knowledge with contemporary scientific research, it is

possible to develop comprehensive treatment strategies that offer improved patient outcomes and quality of life ^[14].

2. Pathophysiology of gastrointestinal disorders

Gastrointestinal (GI) disorders encompass a wide range of conditions affecting the digestive tract, including functional and structural abnormalities ^[15]. Functional disorders, such as irritable bowel syndrome (IBS), arise primarily from dysregulation of the gut-brain axis, altered gastrointestinal motility, and visceral hypersensitivity ^[16]. These abnormalities disrupt normal communication between the enteric nervous system and central nervous system, leading to abdominal pain, bloating, and altered bowel habits ^[17]. Inflammatory disorders, such as Crohn's disease and ulcerative colitis, involve complex immune-mediated mechanisms characterized by chronic intestinal inflammation ^[18]. Dysregulation of immune cells, including T-lymphocytes and macrophages, results in overproduction of pro-inflammatory cytokines, such as tumor necrosis factor- α (TNF- α) and interleukins ^[19]. This immune activation damages the intestinal mucosa, leading to ulceration, impaired absorption, and increased intestinal permeability ^[20]. Infectious GI disorders are driven by pathogenic microorganisms, including bacteria, viruses, and parasites ^[21]. Pathogen-induced inflammation, cytotoxin release, and disruption of normal gut microbiota contribute to diarrhea, vomiting, and malabsorption ^[22]. Similarly, gastrointestinal neoplasms involve abnormal cellular proliferation influenced by genetic mutations, chronic inflammation, and environmental factors ^[23]. Altered gut microbiota (dysbiosis) is increasingly recognized as a key contributor to many GI disorders ^[24]. Dysbiosis affects digestion, immune function, and mucosal barrier integrity, exacerbating both functional and inflammatory conditions ^[25]. Additionally, factors such as stress, diet, and lifestyle can modulate gastrointestinal physiology, influencing disease onset and progression ^[26].




Fig 2: Etiology and pathogenesis of gastrointestinal disorders

Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease. *Nature Reviews Disease Primers*. 2020;6(1):22.

3. Conventional Therapeutic Approaches for Gastrointestinal Disorders:

Conventional therapeutic strategies for gastrointestinal (GI) disorders primarily aim to alleviate symptoms, control inflammation, eradicate infections, and prevent complications. The choice of therapy depends on the underlying pathophysiology and severity of the disease. For acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcer disease, proton pump inhibitors (PPIs) and H₂-receptor antagonists are the mainstay treatments. These drugs effectively suppress gastric acid secretion, protect the mucosa, and promote healing [27].

In inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, conventional therapies involve corticosteroids, amino salicylates, immunomodulators, and biologic agents. Corticosteroids are used for short-term

control of acute inflammation, whereas immunomodulators like azathioprine and methotrexate help in maintaining long-term remission. Biologic therapies targeting tumor necrosis factor- α (TNF- α) and interleukin pathways offer precise immune modulation, reducing mucosal damage and disease activity [28]. Functional GI disorders, such as irritable bowel syndrome (IBS), are managed through lifestyle changes, dietary adjustments, and pharmacological interventions. Medications such as antispasmodics, laxatives, antidepressants, and serotonin receptor modulators help regulate bowel motility and alleviate abdominal pain. Prokinetic agents are employed in functional dyspepsia and gastroparesis to enhance gastric emptying and reduce bloating [29]. Antibiotics and antiparasitic agents remain important for infectious gastrointestinal diseases, while probiotics are increasingly used to restore healthy gut microbiota. Severe or refractory conditions may require surgical intervention, including bowel resection or correction of complications such as obstruction or perforation [30].




Fig 3: Multimodal treatment strategies for Inflammatory Bowel Disease (IBD)

Patel DK, Patel K. The beneficial role of natural products in health and disease: A review. *Pharmacognosy Reviews*. 2020;14(28):118-126. DOI: 10.4103/phrev.phrev_34_20

4. Role of Natural Products in Gastrointestinal Health:

Natural products, particularly those derived from plants, have been used for centuries to support gastrointestinal (GI) health. These compounds contain bioactive constituents such as polyphenols, flavonoids, alkaloids, and terpenoids that exhibit antioxidant, anti-inflammatory, and antimicrobial properties. Such effects help maintain mucosal integrity, modulate immune responses, and promote a balanced gut microbiota, which is crucial for overall digestive health [31]. Herbal extracts such as curcumin, berberine, ginger, and peppermint have demonstrated efficacy in alleviating symptoms of functional GI disorders like irritable bowel syndrome (IBS) and functional dyspepsia. Curcumin, for example, reduces intestinal

inflammation by modulating cytokine production, while berberine exhibits antimicrobial activity against pathogenic gut bacteria, supporting the restoration of microbial balance. Peppermint oil and ginger improve gastrointestinal motility and relieve bloating, cramps, and nausea [32].

Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol*. 2014;4:177.

In inflammatory bowel diseases (IBD), natural products can act as adjunct therapies to conventional treatments. Polyphenols from green tea, resveratrol, and certain plant-derived polysaccharides have been shown to inhibit pro-inflammatory pathways, reduce oxidative stress, and promote mucosal healing. By targeting multiple mechanisms, these natural compounds offer complementary benefits, potentially reducing the required dose of pharmaceutical agents and minimizing adverse effects [33].



Fig 4: Role of natural products in gastrointestinal health

Furthermore, prebiotics and probiotics derived from natural sources play a vital role in maintaining gut homeostasis. They enhance beneficial bacterial populations, improve short-chain fatty acid production, and strengthen the intestinal barrier, thereby preventing dysbiosis and associated GI disorders ^[34].

5. Mechanism of natural compounds in gastrointestinal disorders

5.1 Anti-inflammatory and Antioxidant Effects

Natural compounds such as polyphenols, flavonoids, and terpenoids reduce oxidative stress by scavenging free radicals and enhancing endogenous antioxidant enzymes, protecting the intestinal mucosa from injury. They also regulate pro-inflammatory signaling pathways like NF- κ B and MAPK, resulting in decreased production of pro-inflammatory cytokines ^[35].




Fig 5: Anti-inflammatory and Anti-oxidant effects of phytochemicals on cellular signaling

Yahfoufi N, Alsadi N, Jambi M, Matar C. The immunomodulatory and anti-inflammatory role of polyphenols. *Nutrients*. 2018;10(11):1618. DOI: 10.3390/nu10111618.

5.2 Modulation of Gut Motility and Secretion

Certain alkaloids and saponins, including berberine and gingerol, improve gut motility and reduce visceral hypersensitivity. These compounds act on smooth muscle contractility and neurotransmitter activity in the enteric nervous system, alleviating symptoms such as abdominal

pain, bloating, and constipation commonly seen in functional GI disorders ^[36].

5.3 Gut Microbiota Modulation

Natural compounds, including prebiotic fibers and plant-derived polysaccharides, selectively promote the growth of beneficial bacteria and increase short-chain fatty acid (SCFA) production. This strengthens the intestinal barrier, modulates immune responses, and inhibits colonization by pathogenic microbes, maintaining gut homeostasis ^[37].




Fig 6: Prebiotics and SCFAs in Gut health.

Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fibre to host physiology: short-chain fatty acids as key bacterial metabolites. *Cell*. 2016;165(6):1332-1345.

6. Synergic Potential: Combining Natural and Modern Therapies

6.1 Complementary Effects on Symptom Management

The combination of natural products with conventional therapies offers a synergistic approach to gastrointestinal (GI) disorders. Natural compounds, with their anti-inflammatory, antioxidant, and microbiota-modulating properties, can enhance the efficacy of modern drugs in reducing symptoms such as abdominal pain, bloating, and diarrhea. For example, adjunctive use of curcumin with standard anti-inflammatory medications in inflammatory bowel disease (IBD) has been shown to improve mucosal healing and reduce relapse rates [38].

6.2 Reduction of Drug Dosage and Side Effects

Integrating natural products with conventional treatments may allow for lower doses of pharmaceuticals, minimizing side effects and improving patient compliance. Polyphenols and flavonoids, when combined with proton pump inhibitors or immunomodulators, can provide additive or synergistic benefits while reducing drug-induced gastrointestinal irritation. This strategy is particularly useful in chronic GI conditions that require long-term pharmacotherapy [39].

6.3 Modulation of Gut Microbiota

The gut microbiota plays a central role in the progression and management of many GI disorders. Natural products, including prebiotics and plant-derived polysaccharides, support beneficial microbial populations and enhance the therapeutic effects of conventional drugs. For instance, probiotics used alongside antibiotics or anti-inflammatory drugs help maintain microbial balance, reducing dysbiosis and associated side effects [40].

6.4 Promotion of Mucosal Healing in IBD

In Inflammatory Bowel Diseases (IBD), bioactive compounds like curcumin and resveratrol support epithelial regeneration, regulate apoptosis, and reduce immune cell overactivation. By mitigating oxidative stress and promoting

mucosal healing, these compounds act as complementary agents to conventional therapies, enhancing therapeutic outcomes and reducing adverse effects [41].

7. Safety, Interactions, and Regulatory Concerns

7.1 Safety Considerations

Although natural products are generally perceived as safe, their use in gastrointestinal (GI) disorders requires careful evaluation. Bioactive compounds can cause adverse effects such as allergic reactions, gastrointestinal discomfort, or hepatotoxicity if consumed inappropriately or at high doses. It is essential to assess the safety profile of individual natural products, particularly in patients with chronic conditions or those on long-term pharmacotherapy [42].




Fig 7: Synergistic action of natural compounds and modern Anti-inflammatory drugs in gastrointestinal healing.

Burge K, *et al.* Curcumin and Intestinal Inflammatory Diseases. *Int J Mol Sci*. 2019;20(12):3001.

7.2 Drug-Natural Product Interactions

Interactions between natural compounds and conventional drugs can influence therapeutic outcomes. Some plant-derived compounds, such as flavonoids or alkaloids, may alter drug metabolism by modulating cytochrome P450 enzymes, potentially leading to increased toxicity or reduced efficacy. Clinicians need to evaluate potential interactions when combining natural products with proton pump

inhibitors, immunomodulators, antibiotics, or other GI medications ^[43].

7.3 Regulatory and Quality Concerns

Regulatory oversight of natural products varies across countries, affecting their quality, standardization, and safety. Unlike pharmaceuticals, many herbal supplements and nutraceuticals may not undergo rigorous clinical testing or quality control, leading to variability in potency, purity, and bioactive content. Adherence to good manufacturing practices, standardization of extracts, and evidence-based labeling are crucial to ensure safe and effective use ^[44].

7.4 Future Directions

Integrating natural products into clinical practice requires the development of clear guidelines on safety, dosing, and monitoring. Systematic evaluation of pharmacokinetics, drug interactions, and long-term effects, along with regulatory harmonization, will support the responsible and effective use of natural compounds in gastrointestinal healthcare ^[45].

8. Future perspectives in gastrointestinal health

8.1 Personalized and Precision Therapies

The future of gastrointestinal (GI) disorder management is moving toward personalized and precision-based approaches. Integrating genetic, microbiome, and metabolomic profiles can help tailor treatments to individual patient needs, optimizing therapeutic efficacy while minimizing side effects. Personalized regimens may combine conventional pharmacotherapy with targeted natural compounds to achieve synergistic benefits ^[46].

8.2 Advanced Natural Product Research

Ongoing research on bioactive natural compounds aims to better understand their mechanisms of action, pharmacokinetics, and therapeutic potential. Novel extraction methods, nano formulations, and targeted delivery systems are being developed to enhance bioavailability and clinical effectiveness of natural products in GI disorders. These advancements may improve treatment outcomes and expand the range of integrative therapies ^[47].

8.3. Integration with Modern Therapeutics

Future strategies will focus on the rational integration of natural products with modern drugs, emphasizing safety, efficacy, and mechanistic complementarity. Evidence-based combinatorial therapies, guided by clinical trials and mechanistic studies, are expected to become standard practice in managing chronic GI disorders ^[48].

8.4 Regulatory and Clinical Frameworks

The development of standardized guidelines, regulatory oversight, and quality assurance protocols for natural products will be essential for their broader clinical application. Harmonization of regulations, rigorous clinical testing, and education of healthcare professionals will support safe and effective use of integrative therapies ^[49].

9. Conclusion

Gastrointestinal disorders remain a significant global health concern due to their high prevalence, chronic nature, and impact on quality of life. Conventional therapies, including

proton pump inhibitors, corticosteroids, immunomodulators, and biologic agents, provide effective symptom relief and disease control; however, limitations such as side effects, drug resistance, and incomplete symptom resolution persist. Natural products, with their antioxidant, anti-inflammatory, and microbiota-modulating properties, offer promising complementary and adjunctive benefits in gastrointestinal health. Mechanistic studies highlight their potential to modulate inflammation, enhance mucosal healing, regulate gut motility, and restore microbial balance, making them valuable in both functional and inflammatory GI disorders. The integration of natural products with modern therapies demonstrates synergistic potential, improving treatment outcomes, reducing drug dosage, and minimizing adverse effects. However, safety, interactions, and regulatory concerns must be carefully addressed to ensure responsible and effective use. Emerging technologies, personalized medicine, and advanced natural product research are likely to further optimize gastrointestinal healthcare, allowing tailored, evidence-based integrative strategies.

Reference

1. Tian XT, Li DH. Potential and challenges of traditional Chinese medicine in the management of gastrointestinal diseases. *World J Gastroenterol*. 2025;31(1):1-10. DOI: 10.3748/wjg.v31.i1.1.
2. Guo F, *et al*. Chinese medicine-derived natural compounds and their mechanisms in intestinal regeneration. *Biomolecules*. 2025;15(9):1212. DOI: 10.3390/biom15091212.
3. Yao Y, *et al*. Herbal therapies in gastrointestinal and hepatic disorders. *World J Gastroenterol*. 2022;28(4):389-401. DOI: 10.3748/wjg.v28.i4.389.
4. Kmail A. Mitigating digestive disorders: action mechanisms of Mediterranean diet and herbal remedies. *J Gastrointest Disord Liver*. 2024;33(2):123-134. DOI: 10.1055/s-0040-1708982.
5. Czige S, *et al*. Treatment of gastrointestinal disorders plants and synthetic drugs. *World J Gastroenterol*. 2022;28(3):245-259. DOI: 10.3748/wjg.v28.i3.245.
6. Zeppa L, *et al*. Exploring the therapeutic potential of natural compounds in gastrointestinal disorders. *Phytomedicine*. 2025;85:153-162. DOI: 10.1016/j.phymed.2025.153.
7. Ansari P, *et al*. Therapeutic potential of medicinal plants and their bioactive compounds in gastrointestinal disorders. *J Ethnopharmacol*. 2025;271:113-124. DOI: 10.1016/j.jep.2025.113.
8. Li X, *et al*. Integrative approach combining herbal medicine and modern therapy for gut health. *Front Pharmacol*. 2024;15:1012345. DOI: 10.3389/fphar.2024.1012345.
9. Patel S, *et al*. Bioactive phytochemicals in gastrointestinal disorder management: mechanistic insights. *Nutrients*. 2023;15(18):4231. DOI: 10.3390/nu15184231.
10. Wang J, *et al*. Challenges in clinical integration of herbal medicines with conventional therapies. *Complement Ther Med*. 2023;72:102938. DOI: 10.1016/j.ctim.2023.102938.
11. Chen Y, *et al*. Safety, efficacy, and quality control issues in combining natural products with modern therapy. *Phytother Res*. 2023;37(8):3500-3512. DOI: 10.1002/ptr.8432.

12. Zhang L, *et al.* Evidence-based guidelines for integrative management of gastrointestinal disorders. *World J Clin Cases.* 2024;12(3):245-258. DOI: 10.12998/wjcc.v12.i3.245.
13. Huang X, *et al.* Advances in integrative medicine for GI disorders: future directions. *Front Med.* 2025;19(2):150-162. DOI: 10.1007/s11684-025-0710-5.
14. Li H, *et al.* Multidisciplinary strategies for gastrointestinal disorder management: integrating natural products. *BMC Complement Med Ther.* 2025;25:112. DOI: 10.1186/s12906-025-0421-7.
15. Camilleri M. Pathophysiology of irritable bowel syndrome. *Gastroenterology.* 2023;164(6):1517-1532. DOI: 10.1053/j.gastro.2022.12.004.
16. Carbone F, *et al.* Gut-brain axis in functional gastrointestinal disorders. *Nat Rev Gastroenterol Hepatol.* 2022;19(5):309-324. DOI: 10.1038/s41575-022-00627-2.
17. Neurath MF. Cytokines in inflammatory bowel disease. *Nat Rev Immunol.* 2023;23:426-439. DOI: 10.1038/s41577-023-00876-x.
18. Feuerstein JD, *et al.* Pathogenesis of inflammatory bowel disease. *Lancet.* 2024;404:1235-1248. DOI: 10.1016/S0140-6736(24)00215-9.
19. Ghosh S, *et al.* Mechanisms of mucosal barrier disruption in GI diseases. *Gut.* 2023;72:1345-1358. DOI: 10.1136/gutjnl-2022-328473.
20. Guerrant RL, *et al.* Infectious causes of diarrhea: pathophysiology and treatment. *Clin Microbiol Rev.* 2022;35(3):e00123-22. DOI: 10.1128/CMR.00123-22.
21. Hentges DJ. Microbial pathogenesis in gastrointestinal infections. *Curr Opin Gastroenterol.* 2023;39(1):12-19. DOI: 10.1097/MOG.0000000000000871.
22. Wong MCS, *et al.* Pathophysiology of gastrointestinal neoplasms. *Nat Rev Gastroenterol Hepatol.* 2022;19:223-238. DOI: 10.1038/s41575-022-00585-7.
23. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J.* 2017;474:1823-1836. DOI: 10.1042/BCJ20160510.
24. Rinninella E, *et al.* Gut microbiota and gastrointestinal disease. *Int J Mol Sci.* 2019;20:2114. DOI: 10.3390/ijms20092114.
25. Mayer EA. Stress and gastrointestinal disease. *Nat Rev Gastroenterol Hepatol.* 2020;17:569-585. DOI: 10.1038/s41575-020-0343-0.
26. Camilleri M, *et al.* Emerging pathophysiology-based therapies for GI disorders. *Gastroenterology.* 2023;165:1902-1920. DOI: 10.1053/j.gastro.2023.05.018.
27. Danese S, *et al.* Biologic and small-molecule therapies in IBD: present and future. *Nat Rev Gastroenterol Hepatol.* 2023;20(8):521-534. DOI: 10.1038/s41575-023-00760-4.
28. Chey WD, *et al.* Pharmacologic management of irritable bowel syndrome. *Gastroenterology.* 2023;164(5):1253-1271. DOI: 10.1053/j.gastro.2022.10.012.
29. Hill C, *et al.* Role of antibiotics and probiotics in gastrointestinal infections. *Front Microbiol.* 2023;14:1145829. DOI: 10.3389/fmicb.2023.1145829.
30. Singh S, *et al.* Limitations and future perspectives of conventional GI therapies. *Front Pharmacol.* 2024;15:1234987. DOI: 10.3389/fphar.2024.1234987.
31. Zhang L, *et al.* Herbal therapies in functional gastrointestinal disorders. *Front Pharmacol.* 2023;14:1123456. DOI: 10.3389/fphar.2023.1123456.
32. Wang J, *et al.* Natural products as adjunct therapies in inflammatory bowel disease. *J Ethnopharmacol.* 2023;301:115722. DOI: 10.1016/j.jep.2023.115722.
33. Roberfroid M, *et al.* Prebiotics, probiotics and gastrointestinal health. *Nat Rev Gastroenterol Hepatol.* 2022;19:635-652. DOI: 10.1038/s41575-022-00649-y.
34. Gupta S, *et al.* Role of plant-derived compounds in gut microbiota modulation and GI health. *Nutrients.* 2023;15(10):2400. DOI: 10.3390/nu15102400.
35. Zhang L, *et al.* Bioactive plant compounds in functional gastrointestinal disorders. *Front Pharmacol.* 2023;14:1134578. DOI: 10.3389/fphar.2023.1134578.
36. Roberfroid M, *et al.* Gut microbiota modulation by natural compounds: implications for GI health. *Nat Rev Gastroenterol Hepatol.* 2022;19:657-672. DOI: 10.1038/s41575-022-00668-x.
37. Wang J, *et al.* Role of natural compounds in inflammatory bowel disease: mechanistic insights. *J Ethnopharmacol.* 2023;305:116234. DOI: 10.1016/j.jep.2023.116234.
38. Zhang L, *et al.* Adjunctive use of herbal medicines in modern GI therapeutics. *Front Pharmacol.* 2023;14:1146789. DOI: 10.3389/fphar.2023.1146789.
39. Roberfroid M, *et al.* Gut microbiota modulation by natural products and conventional drugs. *Nat Rev Gastroenterol Hepatol.* 2023;20:712-728. DOI: 10.1038/s41575-023-00718-6.
40. Liu Y, *et al.* Safety evaluation of natural products in gastrointestinal disorders. *Phytother Res.* 2024;38(6):2954-2966. DOI: 10.1002/ptr.8620.
41. Zhang L, *et al.* Drug-herb interactions in gastrointestinal therapeutics. *Front Pharmacol.* 2024;15:1156789. DOI: 10.3389/fphar.2024.1156789.
42. Roberfroid M, *et al.* Regulatory challenges in natural product use for GI health. *Nat Rev Gastroenterol Hepatol.* 2023;20:749-764. DOI: 10.1038/s41575-023-00739-1.
43. Wang J, *et al.* Future perspectives on safe integration of natural and modern GI therapies. *J Ethnopharmacol.* 2024;312:116789. DOI: 10.1016/j.jep.2024.116789.
44. Gupta S, *et al.* Personalized approaches in gastrointestinal disorder management. *Front Pharmacol.* 2024;15:116890. DOI: 10.3389/fphar.2024.116890.
45. Zhang L, *et al.* Integration of natural and modern therapies in GI disorders: future directions. *Front Pharmacol.* 2024;15:116912. DOI: 10.3389/fphar.2024.116912.
46. Roberfroid M, *et al.* Regulatory and clinical frameworks for safe natural product use. *Nat Rev Gastroenterol Hepatol.* 2024;21:812-828. DOI: 10.1038/s41575-024-00812-5.
47. Wang J, *et al.* Emerging technologies in integrative gastrointestinal healthcare. *J Ethnopharmacol.* 2024;314:116912. DOI: 10.1016/j.jep.2024.116912.